Index- P/E- EPS (ttm)-9.50 Insider Own0.90% Shs Outstand107.28M Perf Week-11.11%
Market Cap271.78M Forward P/E- EPS next Y-1.54 Insider Trans0.00% Shs Float50.92M Perf Month-48.01%
Income- PEG- EPS next Q-0.26 Inst Own79.80% Short Float4.83% Perf Quarter-43.64%
Sales- P/S- EPS this Y-40.60% Inst Trans-4.00% Short Ratio4.10 Perf Half Y-84.18%
Book/sh3.09 P/B0.80 EPS next Y-34.10% ROA- Target Price15.78 Perf Year-
Cash/sh3.37 P/C0.74 EPS next 5Y23.00% ROE- 52W Range2.15 - 16.37 Perf YTD-59.74%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-84.85% Beta-
Dividend %- Quick Ratio15.40 Sales past 5Y- Gross Margin- 52W Low15.35% ATR0.42
Employees107 Current Ratio15.40 Sales Q/Q- Oper. Margin- RSI (14)36.92 Volatility9.84% 13.78%
OptionableNo Debt/Eq0.00 EPS Q/Q-113.60% Profit Margin- Rel Volume0.27 Prev Close2.49
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume598.94K Price2.48
Recom1.70 SMA20-17.97% SMA50-33.00% SMA200-60.66% Volume159,276 Change-0.40%
May-12-22 08:00AM  
May-09-22 08:00AM  
May-05-22 04:05PM  
May-03-22 08:00AM  
Apr-29-22 08:15AM  
Apr-14-22 04:10PM  
Apr-07-22 07:08PM  
Mar-30-22 04:39PM  
Mar-10-22 06:12PM  
Feb-15-22 07:00AM  
Feb-01-22 07:57AM  
Jan-10-22 07:00AM  
Dec-21-21 07:00AM  
Dec-09-21 04:30PM  
Dec-05-21 11:01AM  
Nov-01-21 02:26PM  
Oct-31-21 08:21PM  
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Yu DebraSee RemarksMay 04Option Exercise1.711,000,0001,710,0001,000,000May 06 04:15 PM